NCT00299741View on ClinicalTrials.gov

Study of SU11248 in Men With Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Sunitinib

Sunitinib 50 mg daily, 4/2 schedule

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel-Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Massachusetts General Hospital

OTHER

NCT00299741 - Study of SU11248 in Men With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter